These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs. Cheng TL; Chen BM; Chan LY; Wu PY; Chern JW; Roffler SR Cancer Immunol Immunother; 1997 Aug; 44(6):305-15. PubMed ID: 9298932 [TBL] [Abstract][Full Text] [Related]
4. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Cheng TL; Wei SL; Chen BM; Chern JW; Wu MF; Liu PW; Roffler SR Br J Cancer; 1999 Mar; 79(9-10):1378-85. PubMed ID: 10188879 [TBL] [Abstract][Full Text] [Related]
5. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats. Chen BM; Chan LY; Wang SM; Wu MF; Chern JW; Roffler SR Int J Cancer; 1997 Nov; 73(3):392-402. PubMed ID: 9359487 [TBL] [Abstract][Full Text] [Related]
6. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451 [TBL] [Abstract][Full Text] [Related]
7. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Kitamura K; Takahashi T; Yamaguchi T; Noguchi A; Noguchi A; Takashina K; Tsurumi H; Inagake M; Toyokuni T; Hakomori S Cancer Res; 1991 Aug; 51(16):4310-5. PubMed ID: 1868453 [TBL] [Abstract][Full Text] [Related]
8. Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines. Chuang KH; Cheng CM; Roffler SR; Lu YL; Lin SR; Wang JY; Tzou WS; Su YC; Chen BM; Cheng TL Bioconjug Chem; 2006; 17(3):707-14. PubMed ID: 16704208 [TBL] [Abstract][Full Text] [Related]
9. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate. Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980 [TBL] [Abstract][Full Text] [Related]
10. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945 [TBL] [Abstract][Full Text] [Related]
11. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT). Biela BH; Khawli LA; Hu P; Epstein AL Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Wallace PM; Senter PD Bioconjug Chem; 1991; 2(5):349-52. PubMed ID: 1790175 [TBL] [Abstract][Full Text] [Related]
13. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo. Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645 [TBL] [Abstract][Full Text] [Related]
14. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Kitamura K; Takahashi T; Takashina K; Yamaguchi T; Noguchi A; Tsurumi H; Toyokuni T; Hakomori S Biochem Biophys Res Commun; 1990 Sep; 171(3):1387-94. PubMed ID: 2222451 [TBL] [Abstract][Full Text] [Related]
15. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy. Chen BM; Cheng TL; Tzou SC; Roffler SR Int J Cancer; 2001 Dec; 94(6):850-8. PubMed ID: 11745488 [TBL] [Abstract][Full Text] [Related]
16. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869 [TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy. Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts. Deckert PM; Jungbluth A; Montalto N; Clark MA; Finn RD; Williams C; Richards EC; Panageas KS; Old LJ; Welt S Int J Cancer; 2000 Aug; 87(3):382-90. PubMed ID: 10897044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]